←
PCF Science10,899 posts
PCF Science avatar✓

PCF Science ✓

@PCF_Science

The official Twitter account for scientific news from the Prostate Cancer Foundation. Follow us at @PCFNews @ PCF-science.bsky.social

◷ Joined October 2016▧ 1,209 Photos and videos
Toni Choueiri, MD avatar
⟳ PCF Science retweeted
Toni Choueiri, MD@DrChoueiri·Oct 24

Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV melanoma (HR 0.58). A major step for cancer vaccines! #ESMO26 @OncoAlert @myESMO #ESMO26

Post attachmentPost attachment
Toni Choueiri, MD avatar
⟳ PCF Science retweeted
Toni Choueiri, MD@DrChoueiri·Oct 23

Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert

Post attachmentPost attachmentPost attachmentPost attachment
Scott Eggener avatar
⟳ PCF Science retweeted
Scott Eggener@uroegg·Oct 14

UCLA Urology has a long history of impactful basic science discoveries, clinical innovation, practice-changing trials, FDA drug/imaging approvals, and mentorship of future leaders. We are hiring a Vice-Chair of Research: recruit.apo.ucla.edu/JPF1131… DM if questions/nominations

Michael Hofman avatar
⟳ PCF Science retweeted
Michael Hofman@DrMHofman·Oct 19

Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26 @EANM_NucMed Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025). So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles: - Remarkably well tolerated: just 1 grade 3 toxicity (anaemia) - PSA50 response 75%, PSA90 response 33% - Median PSA-PFS and rPFS not reached The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway. Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC @pros_tic team who made this investigator-initiated trial possible. Grateful to @Isotopia_Global and the for their support #TOP (Top Rated Oral Presentation)

Adam B. Weiner, MD avatar
⟳ PCF Science retweeted
Adam B. Weiner, MD@Adam_Weiner535·Oct 22

🚨 Focal salvage HDR brachy for radiorecurrent #prostatecancer🚨 📜@JCO_ASCO 👥 n=62, intraprostatic radiorecurrence after prior RT, multi-institutional 📊 Phase 1/2, dose-escalated focal salvage HDR, up to 30 Gy in 1 to 2 fractions ⏱️ Median f/u 39.4 mo ✅ No acute grade 3 toxicity; late grade 3 in 2 pts (3.2%) ✅ 3-yr bPFS 62.7%, MFS 85.9% ✅ Higher Decipher GC score tracked w/ worse bPFS, rPFS, MFS; all 4 pts w/ GC >0.85 recurred ⚠️ Small GC subset (n=31), single-arm, hypothesis-generating 🎯 Focal salvage HDR is well tolerated & a genomic classifier may prognosticate 🔗 doi.org/10.1200/JCO-25-02730 @UroOnc @urotoday @UrologyTimes @PCF_Science @Davicioni

Post attachmentPost attachmentPost attachment
Neeraj Agarwal, MD, FASCO avatar
⟳ PCF Science retweeted
Neeraj Agarwal, MD, FASCO@neerajaiims·Oct 13

Exciting opportunity for Urology & med onc trainees and practicing physicians👉Elevate your clinical and leadership skills at the @PCFnews Leadership Academy! 📍Santa Monica | Dec 3–5, 2026 ✅ Expert faculty mentoring ✅ Formal certification ✅ Travel & hotel covered 👉Apply: bit.ly/4dyRWlv @urotoday

Post attachment
Salma Kaochar avatar
⟳ PCF Science retweeted
Salma Kaochar@Kaochar2·Oct 12

Not all prostate cancers follow the same molecular playbook! 🧬 🚨🚨Excited to share our new work in @CellReports, spearheaded by graduate student @RizwanKinza 👏and medical student Sai Manikonda👏, revealing distinct genomic alterations and transcriptional programs associated with SPOP-mutant prostate cancer. Another step toward more biologically informed precision oncology! @BCMFromtheLabs Above all, grateful to the patients who generously contributed their biospecimens to advance cancer research. 💕 A heartfelt thank you to our collaborators for their hard work, support, and invaluable feedback throughout this journey. @CCoarfa @marthamims And a special shout-out to the often-unsung heroes of science—our reviewers! Their thoughtful and constructive feedback made this a stronger manuscript. 💕 Proud of this team and grateful for the support of @BCMDeptMedicine @bcmhouston, @PCF_Science, CDMRP PCRP and @NIH @theNCI 🔗cell.com/cell-reports/fullte…

Hsieh Lab avatar
⟳ PCF Science retweeted
Hsieh Lab@HsiehLab·Oct 7

Of note, @yeonsookim_phd (@theNCI K99/R00 awardee) is on the academic job market, so keep an eye out for her. She is an outstanding RNA and cancer biologist!

CRIS Cancer Foundation avatar
⟳ PCF Science retweeted
CRIS Cancer Foundation@CRISCANCERUK·Oct 8

What an inspiring few days at the Prostate Cancer Foundation Annual Scientific Retreat! 🔬🌍 We were so proud to present two new CRIS Cancer–PCF Young Investigator Awards to Kirsty Hodgson (Newcastle University) and Nicolás Anselmino (VHIO). 🏆 #ProstateCancer

Post attachment